SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. SOURCE Quest Diagnostics About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from ...

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional Office-Based Industries SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior y ...

公司活动 - 公司董事长、首席执行官兼总裁Jim Davis将于2024年5月29日美国东部时间上午10:20，在德克萨斯州奥斯汀举行的2024年Leerink Partners医疗十字路口会议的炉边谈话中，介绍公司战略、业绩以及最新市场发展和趋势 [1] - 炉边谈话和问答环节将在会议期间进行网络直播，可在公司投资者关系页面ir.QuestDiagnostics.com观看；直播结束后24小时内可获取存档网络直播，存档将保留至2024年6月28日 [2] 公司概况 - 公司是诊断信息服务领域的领导者，致力于在医疗生态系统中为人们提供诊断见解，助力改善健康状况 [1][3] - 公司诊断见解源自全球最大的去识别临床实验室结果数据库，可揭示疾病识别和治疗的新途径，激发健康行为并改善医疗管理 [3] - 公司每年为三分之一的美国成年人以及一半的美国医生和医院提供服务，拥有近50,000名员工 [3]

Quest Diagnostics (DGX) recently announced a strategic collaboration with PathAI, a global leader in artificial intelligence-powered pathology technology, aimed at revolutionizing cancer and disease diagnosis. This partnership marks a significant step toward accelerated adoption of AI and digital pathology in Quest Diagnostics’ diagnostic services, promising enhanced quality, speed and efficiency in healthcare.Transformative Acquisition of PathAI Diagnostics AssetsUnder this definitive agreement, Quest Diag ...

SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. Murali Bal ...

Quest Diagnostics (DGX) recently announced a multi-faceted collaboration with PathAI to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under a definitive agreement, the company will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.The latest development builds on Quest Diagnostics’ leadership in oncology and subspecialized path ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 500 Plaza Drive (State of Incorporation) (I.R.S. Employ ...

财务数据和关键指标变化 - 第一季度合并收入为23.7亿美元,同比增长1.5%,基础业务收入增长近6% [35][36] - 总检测量(requisitions)同比增长1.6%,其中收购贡献60个基点 [37] - 每份检测单收入略有上升,主要由于每份检测单的检测数量增加和检测组合结构改善所致 [38] - 报告营业利润为3亿美元,占收入的12.7%,调整后营业利润为3.49亿美元,占收入的14.8% [39] - 报告每股收益为1.72美元,调整每股收益为2.04美元,与去年持平 [40] - 经营活动产生的现金流为1.54亿美元,去年同期为0.94亿美元 [40] 各条业务线数据和关键指标变化 - 医生实验室服务业务基础业务收入增长高个位数,受益于医疗服务需求持续高涨和市场份额增加 [16] - 医院实验室服务业务基础业务收入增长中个位数,医院参考检测业务增长快于疫情前水平 [21] - 消费者自主检测业务收入增长两位数,基础业务收入近乎翻倍 [25] 各个市场数据和关键指标变化 - 医生渠道业务增长强劲,得益于与大型医生集团和大型零售商拥有的医生诊所的良好关系 [16] - 医院渠道业务增长良好,医院参考检测业务增长快于疫情前水平 [21] - 消费者渠道业务增长迅速,主要包括一般健康检查、性病和结核病检测等 [25] 公司战略和发展方向及行业竞争 - 公司战略聚焦于满足核心客户医生、医院和消费者的需求,通过先进诊断服务推动增长 [14][15] - 公司通过收购医院实验室外包业务和独立实验室来推动增长 [15][20] - 公司持续投资自动化和人工智能,提高生产效率、服务水平和质量 [31] - 公司面临FDA拟对实验室自主开发检测服务进行监管的挑战,但有信心应对 [12][13] 管理层对经营环境和未来前景的评论 - 公司受益于医疗服务需求持续高涨,并通过与医生和医院的良好关系以及广泛的医保网络获得新客户 [10] - 公司在先进诊断领域如大脑健康、妇女健康和心血管健康等实现两位数增长 [27][28][29] - 公司有信心通过提高生产效率和服务质量来改善盈利能力 [11] - 公司对2024年全年业绩保持乐观,上调了调整每股收益指引 [41] 问答环节重要的提问和回答 问题1 **Patrick Donnelly 提问** 关于公司利润率的变化,包括Haystack业务的影响 [50] **Jim Davis 回答** 公司利润率变化的主要原因包括:COVID-19检测收入下降、基础业务量增长和生产效率提升 [51][52][53][54][55] 问题2 **Ann Hynes 提问** 一季度业绩超预期但全年指引提升有限的原因 [59] **Sam Samad 回答** 一季度业绩超预期主要是由于基础业务量增长强劲,公司保持谨慎态度对未来几个季度的正常化水平进行预期 [60][61][62][63] 问题3 **Kevin Caliendo 提问** 关于FDA拟对实验室自主开发检测服务进行监管的影响 [67] **Jim Davis 回答** 公司有信心应对新的监管要求,不会对2024年业绩产生影响,未来3-4年内公司将采取应对措施 [69][70][71]

Quest Diagnostics Incorporated’s (DGX) first-quarter 2024 adjusted earnings per share (EPS) of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures.GAAP earnings came in at $1.72 per share, down ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.68%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.14 per share when it actually produced earnings of $2.15, delivering a surprise of 0.47%.Over the last four qua ...